Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Acute exposure of cancer cells to high concentrations of type I interferon (IFN-I) drives
growth arrest and apoptosis, whereas chronic exposure to low concentrations provides …

Features of the cancer epigenome distinguish cancers from their respective cell of origin and
establish therapeutic vulnerabilities that can be exploited through pharmacologic inhibition …

Large-scale genomic profiling of pancreatic cancer (PDAC) has revealed two distinct
subtypes:'classical'and 'basal-like'. Their variable coexistence within the stromal immune …

Pancreatic ductal adenocarcinoma is a highly lethal malignancy, which has now become the
seventh most common cause of cancer death in the world, with the highest mortality rates in …

While pancreatic ductal adenocarcinomas (PDACs) are addicted to KRAS-activating
mutations, inhibitors of downstream KRAS effectors, such as the MEK1/2 kinase inhibitor …

The epigenomic abnormality of pancreatic ductal adenocarcinoma (PDAC) has rarely been
investigated due to its strong heterogeneity. Here, we used single-cell multiomics …

Pancreatic ductal adenocarcinoma (PDAC) is clinically challenging due to late diagnosis
and resistance to therapy. Two major PDAC subtypes have been defined based on …

Our defenses against infection rely on the ability of the immune system to distinguish
invading pathogens from self. This task is exceptionally challenging, if not seemingly …

Telomerase plays a pivotal role in tumorigenesis by both telomere‐dependent and telomere‐
independent activities, although the underlying mechanisms are not completely understood …